DFTX Stock: Price, Earnings History and SEC Filings
Definium Therapeutics, Inc. (DFTX) last traded at $36.33, down 4.29% on the latest session and down 4.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.44 against an analyst estimate of $-0.55, a miss of 161.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DFTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-1.44 | $-0.55 | -161.82% |
| Mar 2026 | May 7, 2026 | $-0.71 | $-0.47 | -51.06% |
| Dec 2025 | Feb 26, 2026 | $-0.45 | $-0.45 | +0.00% |
| Sep 2025 | Nov 6, 2025 | $-0.78 | $-0.52 | -50.00% |
DFTX beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How DFTX reacts to earnings
Across its last 8 earnings releases, DFTX moved 2.8% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +0.00% |
| 2026-05-07 | After close | -4.96% |
| 2026-02-26 | After close | +0.93% |
| 2026-01-12 | Before open | +0.29% |
| 2025-11-06 | After close | +3.17% |
| 2025-10-29 | After close | +3.72% |
| 2025-07-31 | After close | -7.15% |
| 2025-05-08 | Before open | -1.97% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
DFTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$184M | – | – | $-2.06 |
| 2024 | – | -$109M | – | – | $-1.54 |
| 2023 | – | -$96M | – | – | $-2.44 |
| 2022 | – | -$57M | – | – | $-1.84 |
| 2021 | – | -$93M | – | – | $-3.40 |
| 2020 | – | -$34M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DFTX
- 8-K · Sep 14, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 8, 2026Other events, Financial statements and exhibits
- 8-K · Aug 12, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 24, 2026Material agreement, Other events, Financial statements and exhibits
- 424B5 · Jun 24, 2026
- 424B5 · Jun 22, 2026
- 8-K · Jun 22, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 12, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
Insider filing activity
DFTX insiders filed 18 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DFTX news
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026Oct 29, 2026 · finance.yahoo.com
- Definium Therapeutics Announces New Employee Inducement GrantsOct 26, 2026 · finance.yahoo.com
- Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book ValueOct 19, 2026 · finance.yahoo.com
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Medicinal Chemicals & Botanical Products. It is incorporated in British Columbia Canada. Its fiscal year ends in December.